Log in

Relevant bibliographies by topics / Addictovigilance / Journal articles

To see the other types of publications on this topic, follow the link: Addictovigilance.

Journal articles on the topic 'Addictovigilance'

Author: Grafiati

Published: 13 April 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Addictovigilance.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jouanjus, Emilie, Joëlle Micallef, Michel Mallaret, and Maryse Lapeyre-Mestre. "Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions." International Journal of Neuropsychopharmacology 22, no. 8 (June 13, 2019): 528–30. http://dx.doi.org/10.1093/ijnp/pyz033.

Full text

Abstract:

Abstract After the publication of an article discussing the methodological options to detect the diversion potential of prescription drugs, this letter presents the multidimensional functioning of the French Addictovigilance System. This system aims at monitoring all substances with abuse potential, relying on a network of experts specialized in clinical and fundamental pharmacology. For more than 25 years, we have created collaborations with partners at the interface with field data related to substance use and the potential related disorders. When relevant depending on the context, these data sources are explored and crossed to analyze the abuse potential of one given substance. This organizational approach is useful to detect early Addictovigilance warning signals and to take appropriate measures. Generalizing such a multidimensional approach outside France appears an appealing option to move towards more effective Addictovigilance systems at the international level.

APA, Harvard, Vancouver, ISO, and other styles

2

Chavant, François, Alexandra Boucher, Reynald Le Boisselier, Sylvie Deheul, and Danièle Debruyne. "New Synthetic Drugs in Addictovigilance." Therapies 70, no. 2 (March 2015): 179–89. http://dx.doi.org/10.2515/therapie/2015001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Chavant, François, Alexandra Boucher, Reynald Le Boisselier, Sylvie Deheul, and Danièle Debruyne. "Nouvelles drogues de synthèse en addictovigilance." Therapies 70, no. 2 (March 2015): 167–78. http://dx.doi.org/10.2515/therapie/2014235.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Jouanjus, Emilie, Valérie Gibaja, Jean-Pierre Kahn, Françoise Haramburu, and Amélie Daveluy. "Comment identifier un signal en addictovigilance ?" Therapies 70, no. 2 (March 2015): 113–22. http://dx.doi.org/10.2515/therapie/2015009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Daveluy, Amélie, Joëlle Perri-Plandé, Marie Baumevieille, Alexandre Peyré, and Ghada Miremont-Salamé. "Addictovigilance dans les départements d’Outre-Mer." Therapies 73, no. 6 (December 2018): 565. http://dx.doi.org/10.1016/j.therap.2018.09.062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Gibaja, Valérie, Audrey Fresse, Juliana Tournebize, and Maryse Lapeyre Mestre. "Poudre d’opium et addictovigilance : état des lieux." Therapies 76, no. 2 (March 2021): 164. http://dx.doi.org/10.1016/j.therap.2021.01.015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Gentile, Gaétan, Maeva Jego, Michel Spadari, Karolina Griffiths, Emilie Jouanjus, and Joëlle Micallef. "Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?" Fundamental & Clinical Pharmacology 32, no. 6 (August 5, 2018): 643–51. http://dx.doi.org/10.1111/fcp.12401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Lapeyre-Mestre, Maryse. "Identification and tracking of addictovigilance signals in general practice: which interactions between the general practitioners and the French addictovigilance network?" Fundamental & Clinical Pharmacology 32, no. 6 (November 11, 2018): 641–42. http://dx.doi.org/10.1111/fcp.12425.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Jouanjus, Emilie, Valérie Gibaja, Jean-Pierre Kahn, Françoise Haramburu, and Amélie Daveluy. "Signal Identification in Addictovigilance: the Functioning of the French System." Therapies 70, no. 2 (March 2015): 123–31. http://dx.doi.org/10.2515/therapie/2015011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Batisse, A., C. Eiden, R. Le Boisselier, J. Tournebize, A. Boucher, B. Fauconneau, S. Deheul, et al. "New psychoactive substances: French addictovigilance data between 2009 and 2017." Toxicologie Analytique et Clinique 31, no. 2 (May 2019): S42—S43. http://dx.doi.org/10.1016/j.toxac.2019.03.057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Lapeyre-Mestre, Maryse, Alexandra Boucher, Amélie Daveluy, Valérie Gibaja, Emilie Jouanjus, Michel Mallaret, Helene Peyrière, et al. "Addictovigilance contribution during COVID-19 epidemic and lockdown in France." Therapies 75, no. 4 (July 2020): 343–54. http://dx.doi.org/10.1016/j.therap.2020.06.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Marillier, M., A. Batisse, C. Chevallier, and S. Djezzar. "Behavioral disorders and new psychoactive substances abuse, a French case series." European Psychiatry 33, S1 (March 2016): S307. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1050.

Full text

Abstract:

IntroductionRange of drugs has largely increased the past few years, especially with the emergence of the New Psychoactive Substances (NPS) sold online. In front of serious risks they cause on human health, they are more and more regulated by the law.ObjectivesTo describe cases of extreme behavioral disorders and highlight risks of potential forensic complications linked to these consumptions.MethodsWe present a case series of serious auto or hetero-aggressive behavioral disorders related to NPS abuse and notified to the Parisian addictovigilance center.ResultsTwenty cases were identified between 2010 and 2015. Users were exclusively men, with mean age of 35.5 years (min: 20, max: 51). Synthetic cathinones are the predominant class of reported NPS (65%). An association between NPS and sexuality is found in 60% of cases (12); among them cathinones are used by 11 men. We observed 6 deaths among which, 5 were associated to sexual practice. Two cases of consumptions of cathinones induced torture and barbarian acts. Concerning aggressive behavioral disorders, we quote 3 cases of hetero-aggressivity (one by stab wound and 2 others developed an hypersexuality ± exhibitionism) and 9 cases of auto-aggressivity characterized by genital mutilations (1), defenestration (3), suicidal attempt (3), and acute psychiatric disorder with endangering life (2). Only four cases have been confirmed by toxicological analysis.ConclusionBehavioral disorders inducing forensics complications exist with NPS and particularly with cathinones. The problematic is certainly undervalued. A collaboration between addictovigilance and forensic services has to be improved.Disclosure of interestThe authors have not supplied their declaration of competing interest.

APA, Harvard, Vancouver, ISO, and other styles

13

Eiden, Céline, Sarah Leone-Burgos, Anaïs Serre, Louise Carton, Marie Gerardin, Reynald Le Boisselier, Valérie Gibaja, et al. "Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network." Fundamental & Clinical Pharmacology 32, no. 6 (July 23, 2018): 654–62. http://dx.doi.org/10.1111/fcp.12395.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Rousselet, Morgane, Fanny Feuillet, Marie Gerardin, Pascale Jolliet, Jean-Benoit Hardouin, and Caroline Victorri-Vigneau. "The French addictovigilance network clinical assessment: Z-drugs, true false twins." Expert Opinion on Drug Safety 16, no. 9 (June 28, 2017): 1063–69. http://dx.doi.org/10.1080/14740338.2017.1346084.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Lapeyre-Mestre, Maryse, and Mathilde Dupui. "Système de surveillance en addictovigilance : quelles données pharmacoépidémiologiques à l'échelle de l'Europe ?" Therapies 70, no. 2 (March 2015): 147–56. http://dx.doi.org/10.2515/therapie/2015006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Micallef, Joëlle, Elisabeth Frauger, Aurore Palmaro, Quentin Boucherie, and Maryse Lapeyre Mestre. "Un exemple d’investigation d’un phénomène « émergent » en addictovigilance : à propos du méthylphénidate." Therapies 70, no. 2 (March 2015): 191–96. http://dx.doi.org/10.2515/therapie/2015012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Victorri-Vigneau, Caroline, Jean Benoit Hardouin, Morgane Rousselet, Marie Gerardin, Marylène Guerlais, Morgane Guillou, Marie Bronnec, Véronique Sébille, and Pascale Jolliet. "Multicentre study for validation of the French addictovigilance network reports assessment tool." British Journal of Clinical Pharmacology 82, no. 4 (July 28, 2016): 1030–39. http://dx.doi.org/10.1111/bcp.13044.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Batisse, Anne, Juliana Tournebize, Julie Heredia, Leila Chaouachi, Samira Djezzar, and Le Boisselier Reynald. "AddictoVigilance sur le mode de consommation par vapotage de substances psychoactives illicites." Toxicologie Analytique et Clinique 32, no. 4 (December 2020): S18—S19. http://dx.doi.org/10.1016/j.toxac.2020.09.043.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Micallef, Joëlle, and Michel Mallaret. "Les 25 ans des centres d’évaluation et d’information sur la pharmacodépendance-addictovigilance." Therapies 71, no. 4 (September 2016): 375–78. http://dx.doi.org/10.1016/j.therap.2016.05.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Micallef, Joëlle, and Maryse Lapeyre-Mestre. "Addictovigilance : le défi pharmacologique de l’évaluation et de la prévention des substances à risque." Therapies 70, no. 2 (March 2015): 111. http://dx.doi.org/10.2515/therapie/2015017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Roussin, Anne, Odile Doazan d’Ouince, Hélène Géniaux, and Clémence Halberer. "Un exemple d’évaluation de l’abus et de la dépendance en addictovigilance : à propos du tramadol." Therapies 70, no. 2 (March 2015): 203–11. http://dx.doi.org/10.2515/therapie/2014221.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Micallef, J. "Nouveaux produits de synthèse (NPS) et addictovigilance : de la pharmacodynamie théorique aux complications somatiques réelles." Toxicologie Analytique et Clinique 30, no. 2 (June 2018): S44—S45. http://dx.doi.org/10.1016/j.toxac.2018.04.053.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Vodovar, Dominique, and Bruno Megarbane. "Ephenidine, diphenidine and methoxphenidine complications reported to the French Addictovigilance Network: another brick in the wall!" Fundamental & Clinical Pharmacology 32, no. 6 (November 11, 2018): 652–53. http://dx.doi.org/10.1111/fcp.12407.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Dupui, Mathilde, Joëlle Micallef, and Maryse Lapeyre-Mestre. "Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution." Therapies 74, no. 2 (April 2019): 307–14. http://dx.doi.org/10.1016/j.therap.2018.09.078.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Schreck, Benoît, Nicolas Wagneur, Pascal Caillet, Marie Gérardin, Jennyfer Cholet, Michel Spadari, Nicolas Authier, et al. "Cannabinoid hyperemesis syndrome: Review of the literature and of cases reported to the French addictovigilance network." Drug and Alcohol Dependence 182 (January 2018): 27–32. http://dx.doi.org/10.1016/j.drugalcdep.2017.09.038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Micallef, Joëlle, and Michel Mallaret. "Assessment of new psychoactive substances: Opportunities for more interactions between analytical toxicologists and the French Addictovigilance Network." Toxicologie Analytique et Clinique 31, no. 4 (December 2019): 195–96. http://dx.doi.org/10.1016/j.toxac.2019.07.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Peyrière, Hélène, Céline Eiden, Michel Mallaret, and Caroline Victorri-Vigneau. "Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres." Therapies 71, no. 6 (December 2016): 563–73. http://dx.doi.org/10.1016/j.therap.2016.07.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Gérardin, Marie, François Etcheverrigaray, Julien Nizard, Hélène Lomenech, Marylène Guerlais, Pascale Jolliet, and Caroline Victorri-Vigneau. "Patients douloureux chroniques suivis dans un centre d’évaluation et de traitement de la douleur : quelles notifications en addictovigilance ?" Therapies 72, no. 1 (February 2017): 169. http://dx.doi.org/10.1016/j.therap.2016.11.052.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Mezaache, Salim, Franck Turlure, Nathalie Fredon, Joëlle Micallef, and Elisabeth Frauger. "Prévention des surdoses d’opioïdes et diffusion de naloxone : implication d’un CEIP-addictovigilance et illustration avec le projet POP." Therapies 77, no. 6 (November 2022): 761. http://dx.doi.org/10.1016/j.therap.2022.10.017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Daveluy, Amélie, Magali Labadie, Karine Titier, Arnaud Courtois, Françoise Penouil, Nadège Castaing, Françoise Haramburu, et al. "Poisoning by synthetic cathinones: Consumption behaviour and clinical description from 11 cases recorded by the Addictovigilance Centre of Bordeaux." Toxicologie Analytique et Clinique 29, no. 1 (February 2017): 34–40. http://dx.doi.org/10.1016/j.toxac.2016.11.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Djezzar, S., F. Vorspan, D. Chataigner, E. Burin, R. Garnier, and J. P. Lépine. "Mephenesin dependence: A case series." European Psychiatry 26, S2 (March 2011): 29. http://dx.doi.org/10.1016/s0924-9338(11)71740-0.

Full text

Abstract:

IntroductionMephenesin is a central muscle relaxant, acting through a depression of the activity of some neurones in the caudate nucleus. It was proposed as a potential treatment of alcohol withdrawal syndrome in the 50s. This over the counter medicine is now mainly prescribed to treat spasticity or as an adjunctive treatment of painful muscle spasm. We know little about this substance except that side effects are venous thrombosis, haemolysis or cutaneous intolerance. Yet, no case of abuse or dependence has been reported.AimsTo report a series of 5 clinical cases in patients who developed abuse or dependence to mephenesin.MethodsWe performed a systematic search in data bases of both Paris addictovigilance and poison centres from 1999 to 2010. Clinical details were obtained from clinicians when possible. A literature search was also performed to describe mephenesin mechanisms of actions that could be implied.ResultsThree (3) women et 2 men aged 35 to 52 years (m : 43.6) were identified as abusing mephenesin, among which 4 patients had a full DSM IV criteria of dependence. All had a previous history of abuse or substance dependence (alcohol, heroin, codeine, ketamine…).The average mephenesin daily intake was 13 g (9 to 24 g) when the maximum recommended dosage is 3 gr/d. In one case, a withdrawal syndrome was observed (tremor, aggressiveness).ConclusionMephenesin may be abused by patients with previous risk factors, especially a personal history of alcohol dependence.

APA, Harvard, Vancouver, ISO, and other styles

32

Ponté, Camille. "Diagnostic de syndrome malin des neuroleptiques en contexte de consommation de substances dopaminergiques et sérotoninergiques ? Apport des données toxicologiques en Addictovigilance." Toxicologie Analytique et Clinique 32, no. 4 (December 2020): S51—S52. http://dx.doi.org/10.1016/j.toxac.2020.09.025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Le Boisselier, Reynald, Virginie Philippe, Céline Eiden, and Veronique Savignat. "Addictovigilance de la MDMA (ecstasy) en France : l’émergence de « nouvelles substances » ne doit pas éclipser le suivi sanitaire des plus anciennes." Therapies 77, no. 6 (November 2022): 757. http://dx.doi.org/10.1016/j.therap.2022.10.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Marillier, M., A. Batisse, C. Chevallier, L. Laviale, and S. Djezzar. "Cannabinoid hyperemesis syndrome: A Parisian case series." European Psychiatry 41, S1 (April 2017): s869—s870. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1745.

Full text

Abstract:

IntroductionCurrently, cannabis remains the most widely used illicit psychoactive substance in the world. Its main pharmacological properties are known and its use for therapeutic purpose is still expanding. Also, its acute and chronic toxicity become more described, even if some mechanisms of pharmacotoxicology still remain to clarify as the cannabinoid hyperemesis syndrome (CHS).ObjectivesTo describe cases of CHS, to highlight the clinical presentation and all the complexity of the medical exploration for making an accurate diagnosis.MethodWe present a case series of CHS related to cannabis use and notified to the Parisian addictovigilance center.ResultsEight cases were collected between 2011 and 2016. The users are almost exclusively men (7/8), with a median age of 31 years and some of them present a history of psychiatric disorder. All of them report important daily cannabis consumption (up to 15 joints by day) with duration of consumption averaged at 10 years. All patients present recurrences of clinical signs of the syndrome including vomiting (8/8) and abdominal pains (8/8) leading to repeated hospitalizations. Despite the presence of compulsive taking hot showers notion (7/8), specific sign of the CHS, its diagnosis were made by a physician in 5 cases. Carried out medical examinations are often complete, invasive, even going to an explorative laparotomy for one patient.ConclusionThe CHS remains not well known. A better understanding of this syndrome will enable better patient care while avoiding costly spending unnecessary investigations.Disclosure of interestThe authors have not supplied their declaration of competing interest.

APA, Harvard, Vancouver, ISO, and other styles

35

Batisse, A., N. Taright, C. Chevallier, M. Marillier, and S. Djezzar. "“Dual disorder with drugs”: Comparison of two French databases." European Psychiatry 33, S1 (March 2016): S72. http://dx.doi.org/10.1016/j.eurpsy.2016.01.005.

Full text

Abstract:

ContextDual diagnosis (substance used disorders (SUD) and mental illness) represents 3% of general population. Among United States population, 42.3% of SUD patients have psychiatric troubles (without tobacco). Moreover, SUD can concern all psychoactive substances (PAS) or illicit PAS only named “dual disorder with drugs” (DDD).MethodsA quantitative analysis of DDD data from January 2013 to July 2014 of two epidemiological tools has been performed: PMSI database (Programme Médicalisé des Systeme d’Information) hospital discharge data is made up of data providing medical information for all patients discharged in Paris public hospital system (AP–HP) and NOT'S is a vigilance database of spontaneous NOTifications of drug abuse and dependence. We propose a descriptive analysis of DDD in Paris metropolitan area.ResultsWith PMSI, 9.2% of SUD inpatients (n = 617) have DDD, with mean age of 46 years (62% of men). In comparison, NOT'S reports 36% of SUD with DDD (n = 302) with mean age of 39.5 years (68% of men). Suicide attempt is also listed and reach 23% of cases.ConclusionThese two databases (Fig. 1) show the difficulty of DDD diagnosis with the discordance in results. DDD miss in PMSI database since addictovigilance database shows a first prevalence of DDD. Despite the high rates of DDD, the problem is often under diagnosed by clinicians practising. It is also important to promote the collaboration among health care workers (addictologist and psychiatrist) because these patients require intensive mental and substance abuse care.Disclosure of interestThe authors have not supplied their declaration of competing interest.

APA, Harvard, Vancouver, ISO, and other styles

36

Barrangou-Poueys-Darlas, Malcolm, Marie Gerardin, Sylvie Deheul, Marion Istvan, Marylène Guerlais, Pascale Jolliet, Thomas Dejoie, and Caroline Victorri-Vigneau. "Poppers Use and High Methaemoglobinaemia: ‘Dangerous Liaisons’." Pharmaceuticals 14, no. 10 (October 19, 2021): 1061. http://dx.doi.org/10.3390/ph14101061.

Full text

Abstract:

Poppers are legal and largely used in France despite severe side effects, such as methaemoglobinaemia (MetHbia). Our work aimed to assess the prevalence of poppers consumers among patients with a MetHbia higher than or equal to 5% in French university hospitals and its evolution before and after the legalization of poppers in France. We conducted a national multicentre observational retrospective study. All patients for whom at least one MetHbia measurement was performed from 2012 to 2017 in university hospitals where the French addictovigilance network (FAN) is implanted were included. For each MetHbia measurement exceeding or equal to 5%, a return to the clinical file was made by the FAN to assess poppers consumption. We calculated the prevalence of MetHbia exceeding or equal to 5% and 25% and the prevalence of poppers consumption before and after the legalization. A total of 239 (0.14%) patients had a MetHbia level exceeding or equal to 5% with 25 (10.46%) cases of poppers consumption. Poppers consumption represented 68.4% (13 out of 19) of cases with MetHbia greater than or equal to 25%. Poppers consumption among patients with MetHbia exceeding or equal to 5% increased after the legalization from 4.76% to 11.67% (prevalence ratio PR = 2.45, 95% CI = [0.98–8.37], p-value = 0.190). The proportion of patients with a MetHbia level of 25% or more increased after the legalization from 4.76% to 8.63% (PR = 1.81, 95% CI = [0.68–6.82], p-value = 0.374). The use of poppers is very frequently reported by patients with MetHbia greater than or equal to 25%.

APA, Harvard, Vancouver, ISO, and other styles

37

Batisse, A., C. Chevallier, J. Azevedo Correia, M. Martinez, G. Hoizey, M. Chèze, S. Buscail, et al. "Example of alert and reporting system of scopolamine poisoning among Parisian cocaine users at regional, national and European levels." European Psychiatry 41, S1 (April 2017): s858. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1709.

Full text

Abstract:

IntroductionIn the literature, few intoxications are related to scopolamine due to its presence in cocaine, heroin or even in counterfeit rohypnol tablets. Nonetheless, during summer 2016, several cases of non-fatal intoxication appeared in the region of Paris.ObjectivesDemonstrate how clinical detection of rare toxic events are fostered by exchanges in close collaboration with different territorial level.AimsImprove the detection of short toxic epidemic.MethodsSuspected cases of scopolamine poisoning notified to Parisian Addictovigilance centre were reported. Information shared through different levels of the alert process contributed to strengthen their assessment.ResultsSeventeen cases of probable scopolamine poisoning among cocaine users were registered between the 6 and 24 of July. In the first 4 cases, toxicological analysis, of blood samples were scopolamine positive, with high concentration between 7 ng/mL and 25 ng/mL (usual therapeutic range: 0.1 to 1.1 ng/mL). A collected sample of this cocaine powder had a purity of 23.2%, with 15.2% of scopolamine. Half time of scopolamine is longer than half time of cocaine (3–8 hours versus 1–2 hours): this could explain why the observed effects lasted over 24 hours (8/17). Main clinical features were mydriasis (15/17), high blood pressure (12/17), tachycardia (13/17), behavioural disorder with agitation (13/17), hallucinations (5/17), and coma (8/17). Practitioner's responsiveness and the extensive information sharing [MM1] between regional and European level were congruent.ConclusionsAdulterated street drugs can lead to short toxic epidemic which could be unnoticed. Emerging event should require careful assessment with linkage between risk assessors and risk managers.Disclosure of interestThe authors have not supplied their declaration of competing interest.

APA, Harvard, Vancouver, ISO, and other styles

38

Gérardin, Marie, Morgane Rousselet, Pascal Caillet, Marie Grall-Bronnec, Pierre Loué, Pascale Jolliet, and C. Victorri-Vigneau. "French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol." BMJ Open 9, no. 6 (June 2019): e027443. http://dx.doi.org/10.1136/bmjopen-2018-027443.

Full text

Abstract:

IntroductionIn recent years, data collected by the French Addictovigilance Network have shown the potential for abuse and addiction associated with zolpidem (the most sold hypnotic drug in France). Since 10 April 2017, new regulations have come into force that require zolpidem to be prescribed on special secure prescription pads, in order to reduce the risk of abuse or misuse. This measure has far-reaching repercussions that are not only limited to the consumption of zolpidem but also extend to the usage of sedative medication on a whole. The objective of the ZOlpidem and the Reinforcement of the Regulation of prescription Orders (ZORRO) study is to evaluate the overall impact of the new regulatory framework requiring zolpidem to be prescribed on special secure prescription pads. Three axes will be evaluated: the number of consumers, the type of consumption (chronic use versus occasional use, problematic consumption versus non-problematic use) and the consumption of other sedative molecules.The study has been registered in the Protocol Registration and Results System under the numberNCT03584542at stage "Pre-results".Methods and analysisThe ZORRO study is an epidemiological, observational, national multicentre, non-controlled, prospective research project supported by the French National Agency for Medicines and Health Products Safety. The evaluation of the impact of the regulatory framework change relative to zolpidem will be done according to two axes: via an epidemiological study of the French National Health Insurance database and by the implementation of field studies of prescribers and consumers of zolpidem.Ethics and disseminationThe Nantes Research Ethics Committee (Groupe Nantais d’Ethique dans le Domaine de la Santé), the Committee for the Protection of the Population and the Committee of Expertise in Research, Studies and Evaluations in the Field of Health approved this study. Results will be presented in national and international conferences and submitted to peer-reviewed journals.Trial registration numberNCT03584542; Pre-results.

APA, Harvard, Vancouver, ISO, and other styles

39

Lapeyre-Mestre, Maryse. "Addictovigilance in women, the hidden part of the iceberg?" Therapies, October 2022. http://dx.doi.org/10.1016/j.therap.2022.10.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Batisse, Anne, Céline Eiden, Sylvie Deheul, Emilie Monzon, Samira Djezzar, and Hélène Peyrière. "Chemsex practice in France: An update in Addictovigilance data." Fundamental & Clinical Pharmacology, September 14, 2021. http://dx.doi.org/10.1111/fcp.12725.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Guerlais, Marylène, Aurélie Aquizerate, Arthur Lionnet, Amélie Daveluy, Mélanie Duval, Marie Gérardin, Marion Istvan, Edouard-Jules Laforgue, and Caroline Victorri-Vigneau. "Nitrous oxide: a unique official French addictovigilance national survey." Frontiers in Public Health 11 (May 3, 2023). http://dx.doi.org/10.3389/fpubh.2023.1167746.

Full text

Abstract:

IntroductionNitrous oxide has become over the last few years a public health problem in many countries. France has a dedicated health monitoring system dedicated to the surveillance of the abuse, dependence and consequences associated with the use of psychoactive substances coordinated by the French National Agency for the Safety of Medicines and Health Products.We present the French national survey of nitrous oxide.Materials and methodsWe analyzed all the cases with nitrous oxide from 2012 to 2021: number of notifications, characteristics of the subjects and consumption, consequences reported and their evolutions over time. In addition, we have made a special focus on the four main complications reported.ResultsA total of 525 cases were received with an exponential increase since 2019. We observed changes in the characteristics of the notifications with an increase in the proportion of women [42.7% in 2021 vs. 30.8% in 2020 (p = 0.02)]; an increase in the quantities consumed (use of cylinders); a negative evolution of the contexts of use with a search for self-therapeutic effects and use in violent contexts; an increasing trend of the severity of cases [78.1% in 2021 vs. 70.0% in 2020 (p = 0.07)].The main effects were substance use disorders and/or associated criteria (82.5%), neurological disorders (75.4%), psychiatric symptoms (15.4%) and cardiovascular events (8.6%). In terms of evolution, we observed a significant increase in cases with a use disorder and an increase in neurological complications. Moreover, new serious effects, notably cardiovascular events were reported.DiscussionThe combination of high availability, varied effects from euphoria to relief of discomfort in a stressful global pandemic context and the development of dependence could explain the rapid growth of consumption and the seriousness of the cases.It must now be taken into account that (i) Substance use disorders are associated with nitrous oxide consumption; (ii) clinicians must consider “nitrous oxide” in young subjects presenting different types of manifestations; and (iii) stopping consumption is imperative and is the first treatment. In this context, an addictological assessment must also be carried out.

APA, Harvard, Vancouver, ISO, and other styles

42

Tambon, Marine, Camille Ponté, Emilie Jouanjus, Nathalie Fouilhé, Joelle Micallef, and Maryse Lapeyre-Mestre. "Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance." Frontiers in Psychiatry 12 (February 3, 2021). http://dx.doi.org/10.3389/fpsyt.2021.639780.

Full text

Abstract:

Introduction: Gabapentinoid drugs (gabapentin and pregabalin) are widely used worldwide for epileptic and pain disorders. First signals of gabapentinoid abuse occurred in the last decade. This study aims to describe clinical characteristics of gabapentinoid use related disorders and health consequences in France.Materials and Methods: We designed a multisource investigation reviewing data reported to the French Addictovigilance Network (FAN) with pregabalin and gabapentin from 2010 to 2019. Information was obtained through the analysis of Spontaneous Reports (SRs) notified by health professionals and the pharmacoepidemiological surveys OSIAP (suspicious prescriptions forms indicators of potential abuse), OPPIDUM (observation of illicit drugs and misuse of psychotropic medications), DRAMES (death related to prescription drugs and other substances), and DTA (toxic deaths due to analgesics).Results: Over 2010–2019 period, were collected: (i) 265 SRs (258 pregabalin; 7 gabapentin); (ii) 816 forged prescription forms (805 pregabalin, 10 gabapentin, 1 involving both drugs); (iii) 145 cases of gabapentinoid use in people who use drugs (121 pregabalin; 24 gabapentin) and (iv) 31 cases of gabapentinoid-related deaths (25 pregabalin; 6 gabapentin). Risk factors of gabapentinoid abuse were opioid use disorders or psychiatric history, but cases of primary abuse in subjects without any substance abuse history were observed. Adverse outcomes concern almost exclusively pregabalin, with coma, dyspnea, convulsion, and conduction disorders. Treatment demands increased from 10.6% in 2018 to 23.1% in 2019, with pregabalin cited as the first substance leading to addictological care in the 2019 OPPIDUM survey. Gabapentinoid-related deaths increased over time. Pregabalin has become the first drug mentioned in forged prescriptions in 2019 (23.8% of OSIAP), while it ranked at the 15th position in 2017 (2.6%).Discussion: This study shows the importance of addictovigilance monitoring for gabapentinoids. Addictovigilance data helped to make visible the gabapentinoid-abuse related health harms (hospitalization for serious neurologic, psychiatric or cardiac effects, requests for addictological support and deaths) and to confirm the intrinsic abuse potential of pregabalin. These data highlight new points of vigilance considering observed primary abuse. At this point in France, the risk of abuse and related complications is very apparent with pregabalin. Still, it is identical to that observed elsewhere with gabapentin.

APA, Harvard, Vancouver, ISO, and other styles

43

"Erratum: Nitrous oxide: a unique official French addictovigilance national survey." Frontiers in Public Health 11 (July 4, 2023). http://dx.doi.org/10.3389/fpubh.2023.1235720.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Aquizerate, Aurélie, Edouard-Jules Laforgue, Marion Istvan, Morgane Rousselet, Marie Gérardin, Emilie Jouanjus, Frédéric Libert, et al. "Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study." International Journal of Mental Health and Addiction, May 31, 2023. http://dx.doi.org/10.1007/s11469-023-01078-y.

Full text

Abstract:

AbstractZopiclone, like zolpidem, is under surveillance in France due to its potential for dependence, abuse and misuse. However, part of the narcotics regulation was implemented in 2017 in France for zolpidem only, which has led to an increase in the number of zopiclone consumers. The objective of this article is to present French addictovigilance data regarding the evolution of the abuse, dependence and misuse profiles of zopiclone. We used the following 3 data sources over two periods: the 3-year period before the regulatory measure regarding zolpidem (2014–2016) and the 3-year period after the regulatory measure (2018–2020): (i) Medic'AM, a public database which provides a good overview of the number of boxes of zopiclone reimbursed in France; (ii) all French cases of drug dependence or abuse reported by health professionals to the French Addictovigilance Network (FAN); and (iii) a national epidemiological tool based on the surveillance of falsified prescriptions. Between the first and the second study periods (i) despite an increase in the exposure of the population to zopiclone, the proportion of reports to the FAN remained stable; (ii) the proportion of misusers increased significantly (p < 0.01), from 27% (n = 31) to 48.3% (n = 72); (iii) the profile of problematic users remained comparable with persistence of markers of problematic use; and (iv) there was a significant increase (p = 0.01) in zopiclone fraud for obtention, from 26.1% (n = 30) to 40.9% (n = 61), which mainly concerned nomadism. Prescribers should remain cautious in providing zopiclone prescriptions.

APA, Harvard, Vancouver, ISO, and other styles

45

Diaz, Laurine, Céline Eiden, Emilie Jouanjus, Elisabeth Frauger, Nathalie Fouilhé, Samira Djezzar, Valérie Gibaja, et al. "Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020." Therapies, February 2023. http://dx.doi.org/10.1016/j.therap.2023.02.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Eiden, Céline, Marc Vincent, Chris Serrand, Anais Serre, Nathalie Richard, Marie‐Christine Picot, Elisabeth Frauger, Nathalie Fouilhé, Amélie Daveluy, and Hélène Peyrière. "Health consequences of cocaine use in France: data from the French Addictovigilance Network." Fundamental & Clinical Pharmacology, October 2, 2020. http://dx.doi.org/10.1111/fcp.12603.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Bouquet, Emilie, Stéphanie Pain, Céline Eiden, Emilie Jouanjus, Nathalie Richard, Bernard Fauconneau, Marie‐Christine Pérault‐Pochat, et al. "Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)." British Journal of Clinical Pharmacology, April 19, 2021. http://dx.doi.org/10.1111/bcp.14812.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Bouquet, Emilie, Céline Eiden, Bernard Fauconneau, Charlotte Pion, Carton Louise, Chevalier Cécile, Daveluy Amélie, et al. "Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020." Scientific Reports 12, no. 1 (October 3, 2022). http://dx.doi.org/10.1038/s41598-022-19197-2.

Full text

Abstract:

AbstractCannabis is the main illicit psychoactive substance used by pregnant women in France. The aim of the present national survey was to describe adverse events (AEs) of recreational cannabis use during pregnancy reported to the French Addictovigilance Network (FAN). Spontaneous reports (SRs) of AEs related to recreational cannabis use during pregnancy were collected by the FAN between 01/01/2011 and 31/01/2021 (excluding cannabidiol and synthetic cannabinoids). Over the study period, 160 SRs involved cannabis use alone or in association with tobacco (59% of all SRs) which increased. Among the 175 maternal AEs, the most commons were psychiatric AEs experienced by 96 (64.9%) women, in particular cannabis use disorders (n = 89, 60.1%), dependence (n = 54, 36.5%) and abuse (n = 21, 14.2%). Among the 57 fetal AEs, the most common were heart rhythm disorders that affected 25 (16.9%) fetuses and intrauterine growth restriction (IUGR) (n = 20, 13.5%). Among the 140 neonatal AEs, the most common were IUGR experienced by 39 (26.3%) newborns and prematurity (n = 32, 21.6%). Twelve cases of congenital malformations were observed and 4 intrauterine/neonatal deaths. Furthermore, some of these AEs (n = 13) were unexpected. Cannabis use during pregnancy has problematic consequences for both mothers and infants who need close monitoring.

APA, Harvard, Vancouver, ISO, and other styles

49

Roussin, Anne, Thomas Soeiro, Charlotte Fouque, Emilie Jouanjus, Elisabeth Frauger, Nathalie Fouilhé, Michel Mallaret, et al. "Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data." British Journal of Clinical Pharmacology, April 5, 2022. http://dx.doi.org/10.1111/bcp.15323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Gandolfo, Pauline, Thomas Soeiro, Élisabeth Jouve, Bruno Revol, Amélie Daveluy, Célian Bertin, Céline Eiden, et al. "Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network." Fundamental & Clinical Pharmacology, February 19, 2024. http://dx.doi.org/10.1111/fcp.12995.

Full text

Abstract:

AbstractBackgroundDue to its psychoactive effects, ketamine has become a drug used for non‐medical purpose.ObjectivesTo assess the latest trends in ketamine use among people with substance use disorder and to characterize its clinical complications using complementary health data sources of the French Addictovigilance Network.MethodsFirst, we extracted all reports involving ketamine from 2012 to 2021 from the database of the OPPIDUM program (i.e., a multicentric program conducted in collaboration with hundreds of substance abuse treatment facilities that collects data on drugs used by subjects with substance use disorders). We described the reports globally and the changes from 2012 to 2021. Second, we extracted all cases involving ketamine from July 2020 to December 2022 from the French National Pharmacovigilance Database (BNPV). We identified the cases related to ketamine use among people with substance use disorder and described them.ResultsThere was a 2.5‐fold increase in the number of ketamine users with substance use disorder in the OPPIDUM program, from 35 (0.7%) subjects in 2012 to 89 (1.7%) subjects in 2021. There was an increase in the proportion of subjects who were daily users, had distress upon discontinuation, and presented addiction. There were 238 cases related to ketamine use among people with substance use disorder in the French National Pharmacovigilance Database from July 2020 to December 2022. Among them, 94 (39.5%) cases involved ketamine use disorder, 20 (8.4%) cases involved urinary tract and kidney symptoms, and 13 (5.5%) cases involved hepatobiliary symptoms.ConclusionThe trend observed over 10 years reflects the growth in ketamine use among people with substance use disorder, although it does not allow to estimate the rates of non‐medical use of ketamine in the general population. Ketamine‐induced uropathy and cholangiopathy are reported in ketamine users with substance use disorder, especially in case of repeated and/or prolonged use of high doses.

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!